Balance Sheet (Annual)

ORGS / Orgenesis, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash Equivalents At Carrying Value 1 0 51 1,314 4,168 891 3,519
    Accounts Receivable Net Current - - - - 1,173 1,229 1,336
    Prepaid Expense Current 1 28 37 105 1,118 779 841
    Receivables Net Current - - - - - - 691
    Grants Receivable - - - - 1,446 906 183
    Inventory Net - - - - 301 400 725
    Assets Current 2 39 98 2,230 8,206 4,205 7,295
Assets Noncurrent
  Prepaid Pension Costs - 1 4 6 - - -
  Derivative Assets Noncurrent - - - - - - 339
  Investments - - - - - - 1,321
  Property Plant And Equipment Net - 8 13 13 4,296 4,573 5,104
  Restricted Cash And Cash Equivalents - - - - 5 5 -
  Intangible Assets Net Excluding Goodwill - - - - 16,653 15,050 15,051
  Goodwill - - - - 9,535 9,584 10,684
  Other Assets Noncurrent - - - - 53 70 78
  Assets Noncurrent - - - - 30,542 29,282 32,577
Assets 2 48 114 2,249 38,748 33,487 39,872
Liabilities And Stockholders Equity
  Liabilities Current
    Short Term Bank Loans And Notes Payable - - - 14 - 21 0
    Accounts Payable Current 45 136 139 1,084 3,475 4,554 3,914
    Accrued Liabilities Current - 73 386 375 816 1,205 1,435
    Employee Related Liabilities Current - 76 155 626 1,348 1,680 2,961
    Due To Related Parties Current 36 42 42 42 42 42 116
    Advance Payment On Account Of Grant - - - 85 307 243 1,719
    Notes Payable Current - - - - 2,829 1,111 378
    Deferred Revenue Current - - - - 1,216 1,273 3,611
    Convertible Debt Current - - - - - 2,541 2,780
    Convertible Bonds - - - - 1,888 1,818 0
    Derivative Liabilities Current - - - - 1,533 76 -
    Investments In Associate Net - - - - - 12 0
    Liabilities Current - 327 986 4,663 16,476 14,576 16,914
  Liabilities Noncurrent
    Long Term Loans Payable - - - - - - 2,118
    Convertible Debt Noncurrent - - - - - 1,059 2,415
    Warrants And Rights Outstanding - - 1,158 560 1,382 1,843 -
    Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent - - 4 5 5 5 6
    Derivative Liabilities Noncurrent - - - - - 273 0
    Deferred Income Taxes And Other Liabilities Noncurrent - - - - 3,327 1,862 690
    Liabilities Noncurrent - - 1,162 565 7,254 8,333 5,229
  Liabilities 85 329 2,149 5,228 23,730 22,909 22,143
Commitments And Contingencies - - - - 0 0 -
Redeemable Common Stock - - - - 21,458 0 -
Redeemable Non Controlling Interest - - - - - - 3,606
Stockholders Equity
  Common Stock Value 8 5 5 6 6 12 1
  Additional Paid In Capital 47 4,850 8,635 13,153 14,229 41,605 55,334
  Common Stock Share Subscribed But Unissued Subscriptions Receivable - - - -60 -1,251 0 -1,483
  Accumulated Other Comprehensive Income Loss Net Of Tax - - - -18 -1,286 -1,205 1,425
  Retained Earnings Accumulated Deficit - - - -16,179 -20,640 -29,834 -44,120
  Stockholders Equity -83 -281 -2,034 -2,979 -6,440 10,578 14,123
  Liabilities And Stockholders Equity 2 48 114 2,249 38,748 33,487 39,872

Peers - Pharmaceutical Preparations (2834)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 68619K105